Antidepressants and risks of suicide and suicide attempts: a 27-year observational study
- PMID: 21658345
- PMCID: PMC3643209
- DOI: 10.4088/JCP.10m06552
Antidepressants and risks of suicide and suicide attempts: a 27-year observational study
Abstract
Objective: The 2007 revision of the black box warning for suicidality with antidepressants states that patients of all ages who initiate antidepressants should be monitored for clinical worsening or suicidality. The objective of this study was to examine the association of antidepressants with suicide attempts and with suicide deaths.
Method: A longitudinal, observational study of mood disorders with prospective assessments for up to 27 years was conducted at 5 US academic medical centers. The study sample included 757 participants who enrolled from 1979 to 1981 during an episode of mania, depression, or schizoaffective disorder, each based on Research Diagnostic Criteria. Unlike randomized controlled clinical trials of antidepressants, the analyses included participants with psychiatric and other medical comorbidity and those receiving acute or maintenance therapy, polypharmacy, or no psychopharmacologic treatment at all. Over follow-up, these participants had 6,716 time periods that were classified as either exposed to an antidepressant or not exposed. Propensity score-adjusted mixed-effects survival analyses were used to examine risk of suicide attempt or suicide, the primary outcome.
Results: The propensity model showed that antidepressant therapy was significantly more likely when participants' symptom severity was greater (odds ratio [OR] = 1.16; 95% CI, 1.12-1.21; z = 8.22; P < .001) or when it was worsening (OR = 1.69; 95% CI, 1.50-1.89; z = 9.02; P < .001). Quintile-stratified, propensity-adjusted safety analyses using mixed-effects grouped-time survival models indicate that the risk of suicide attempts or suicides was reduced by 20% among participants taking antidepressants (hazard ratio, 0.80; 95% CI, 0.68-0.95; z = -2.54; P = .011).
Conclusions: This longitudinal study of a broadly generalizable cohort found that, although those with more severe affective syndromes were more likely to initiate treatment, antidepressants were associated with a significant reduction in the risk of suicidal behavior. Nonetheless, we believe that clinicians must closely monitor patients when an antidepressant is initiated.
© Copyright 2011 Physicians Postgraduate Press, Inc.
Comment in
-
In people taking antidepressants, suicidal behaviour is less common when they are taking them than in unexposed periods.Evid Based Ment Health. 2011 Nov;14(4):98. doi: 10.1136/ebmh.2011.100157. Epub 2011 Sep 30. Evid Based Ment Health. 2011. PMID: 21963710 No abstract available.
-
Antidepressant use and risk for suicide attempts in bipolar disorder.J Clin Psychiatry. 2011 Dec;72(12):1697; author reply 1697. doi: 10.4088/JCP.11lr07372. J Clin Psychiatry. 2011. PMID: 22244027 No abstract available.
References
-
- United States Food and Drug Administration. [Accessed February 7, 2011];Briefing document for Psychopharmacologic Drugs Advisory Committee. 2006 Dec 13;:page 38. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272bl-OJ-FDA.pdf.
-
- United States Food and Drug Administration. [Updated February25, 2009. Accessed February, 2011];Labeling change request letter for antidepressant medications. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096352.htm.
-
- United States Food and Drug Administration. [Accessed February 7, 2011];Revisions to product labeling. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM....
-
- Keitner GI, Pasternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? l Clin Psychiatry. 2003;64(9):1091–1093. - PubMed
-
- Zimmerman M, Mattia JI, Pasternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469–473. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 2 R01 MH025416-34A2/MH/NIMH NIH HHS/United States
- R01 MH023864/MH/NIMH NIH HHS/United States
- 2 R01 MH032864-34A2/MH/NIMH NIH HHS/United States
- 2 R01 MH029957-34-A2/MH/NIMH NIH HHS/United States
- R01 MH025430/MH/NIMH NIH HHS/United States
- R01MH60447/MH/NIMH NIH HHS/United States
- R01 MH060447/MH/NIMH NIH HHS/United States
- R01 MH025416/MH/NIMH NIH HHS/United States
- R01 MH029957/MH/NIMH NIH HHS/United States
- 2 R01 MH025430-34A2/MH/NIMH NIH HHS/United States
- R01 MH025478/MH/NIMH NIH HHS/United States
- U01 MH025478/MH/NIMH NIH HHS/United States
- 2 R01 MH025478-34A2/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
